Canopy Growth’s views
It will be interesting to see how Canopy Growth (WEED) and ebbu develop products targeting the adult-use and medical hemp markets while staying within US regulatory boundaries. A November 26 press release reported that “Canopy Growth, through a newly formed subsidiary, will employ ebbu’s assets and personnel to conduct R&D.[1.research and development] There will be no production or sale of products resulting from such R&D in the United States unless and until it would be federally legal to do so.”
However, in a December 20 press release, Canopy commented on its position to capture the US market (MJ), stating that with the company’s “deep hemp-specific portfolio of intellectual property acquired from Colorado-based ebbu Inc. and a landmark investment of USD $4 billion from Constellation Brands, management believes it is well-positioned to enter the US market quickly.” It added that it will provide more details next year.
With hemp’s legalization, what products could we see in US markets from cannabis companies such as Tilray (TLRY), CannTrust (CNTTF), Aurora Cannabis (ACB), and Cronos Group (CRON)? As shown in the graph above, Cronos has outperformed the ETFMG Alternative Harvest ETF this year. Continue reading for a look at some products that could be developed.